First of all: i am here to learn. I appreciate every critical Feedback on this very basic analysis.
If the double bottom within the box will be confirmed (so price over about 230, it will open a trend in the direction of 300.
But if we fail the (about) 208 USD resistance, we could assume a downtrend.
It will be very interesting in the next days.
Similarities can be seen in red,yellow,green
The breakabove the fib circle level, which has previously been seen as a strong resistance point is an extremely good sign
along with the possible development of a vaccine for a new variant (if the current vaccine isn't effective)
NVAX looks bullish
The paper returns to the support zone. Now there is strong news on the creation of a new generation of coronovirus vaccine. It's still relevant right now. The potential is as high as $300. That's +80%. But don't forget to lock in your position as early as possible.
❤️ If you find this helpful and want more FREE forecasts in TradingView
. . . . . Please show...
Pfizer's monopoly is very strong on the Covid-19 vaccines . They are spending millions hiding their side effects and creating hurdles for their competitors at the regulatory agencies SUCCESSFULLY . It maybe that Novavax has one the best products out there but that simply does not matter at this point , we know how powerful big pharma can be and Novavax's lateness...
In short, they most likely bounce from this level for a short time, but whether they continue their bull run or not depends on price action in the next couple weeks. I have some remarks on the charts that might help following up with their moves. The RSI for all three companies are in oversold area and historically we have seen them move back up when they hit 30...
NVAX has had two inside days in a row and the flow looks negative. I can see falling down to $185 and if it blows through that pivot all the way down to $175
NVAX looks great; if it can break above resistance around $222, then it should be able to test 241, 258 next. The 50 EMA recently dipped below the 200 for a couple weeks at the beginning of November, it appears to have crossed and broken above the 200 EMA again, which is a pretty good bullish indicator. MACD looks like it has bullish momentum as well.
With...
Supply Zone
11/04 earning
Short Entry 162
Stop 175
Target1 120
Target2 80
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
The same result? Nine out of ten chance of this worst stock to buy right now. Among this brand stock are two components if your currently holding this company, especially for the long term, you're not OK – this is simply places where investors should avoid putting new money at the moment.
Lots to like here - heavily abused over the past month, bouncing off previous relative low/support, possible falling wedge break to the upside, MACD starting to turn up, 50 and 200 day MAs around the 190-200 level. 160 looks almost certain while 180 is not out of the question. might take a few sessions to pop through - earnings coming up early november.
Looks like a head and shoulders top and the neckline was broken a while back. Bad news about the vaccine caused a gap down. Appears NVAX has hit the 100% down target for the ugly top, but does not always mean it is over as it can be an extension as well.
Sometimes looking at a candle that forms on the day of the gap down can help. This one made large gains at...
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
NASDAQ
